prodrug


Also found in: Medical, Encyclopedia, Wikipedia.

pro·drug

 (prō′drŭg′)
n.
Any of various drugs that are administered in an inactive form and converted into active form by normal metabolic processes.

prodrug

(ˈprəʊˌdrʌɡ)
n
(Biochemistry) a compound that is itself biologically inactive but is metabolized in the body to produce an active therapeutic drug

pro•drug

(ˈproʊˌdrʌg)

n.
an inactive substance that is converted to a drug within the body by the action of enzymes or other chemicals.
References in periodicals archive ?
KP879 is KemPharm's prodrug product candidate which is also based on SDX and intended for the treatment of Stimulant Use Disorder.
TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men.
NB1111 is Nemus'proprietary prodrug of tetrahydrocannabinol (THC) that is currently in development for the treatment of glaucoma.
Eskil Elmr, CSO NeuroVive commented We are excited to be able to supply compounds from our succinate prodrug family designated exclusively for research use to the scientific community.
LPCN 1144, an oral prodrug of bioidentical testosterone, is being developed as a treatment of non-alcoholic steatohepatitis and is currently being studied in a proof-of-concept MRI PDFF based liver fat imaging clinical study.
In a movement to develop less-toxic anticancer drugs, recent attention has been focused on the use of prodrugs. A prodrug remains inactive until it reaches diseased cells at which time it becomes activated and cytotoxic.
Tumor-tropic neural stem cells (NSCs) have been engineered to localize a variety of therapeutic agents to invasive brain tumors [1], with NSC-mediated enzyme prodrug treatment strategy being the first to be tested clinically.
Pharmacologists neutralized this property by attaching a small peptide to create a prodrug called Mipsagargin, which responds to enzymes released by some types of cancer cells.
The company's lead product candidate Mipsagargin, a novel prodrug therapeutic for cancer, is being developed initially for hepatocellular carcinoma, or liver cancer.
(VTGN) said that the European Patent Office (EPO) has issued a notice of intention to grant the company's patent application for its oral CNS prodrug candidate in Phase 2 development for major depressive disorder (MDD).
A prodrug is a modified biologically active compound that will release the active compound in vivo following enzymatic or chemical cleavage.
As presented in Figures 2 and 3, all examined compounds inhibited the activity of AChE; however, prodrug 2 only inhibited up to 21.2% at a concentration of 3 [micro]mol/mL.